Invasive Diagnostic Procedures from Bronchoscopy to Surgical Biopsy—Optimization of Non-Small Cell Lung Cancer Samples for Molecular Testing

Background and Objectives: Treatment of advanced lung cancer (LC) has become increasingly personalized over the past decade due to an improved understanding of tumor molecular biology and antitumor immunity. The main task of a pulmonologist oncologist is to establish a tumor diagnosis and, ideally, to confirm the stage of the disease with the least invasive technique possible. Materials and Methods: The paper will summarize published reviews and original papers, as well as published clinical studies and case reports, which studied the role and compared the methods of invasive pulmonology diagnostics to obtain adequate tumor tissue samples for molecular analysis, thereby determining the most effective molecular treatments. Results: Bronchoscopy is often recommended as the initial diagnostic procedure for LC. If the tumor is endoscopically visible, the biopsy sample is susceptible to molecular testing, the same as tumor tissue samples obtained from surgical resection and mediastinoscopy. The use of new sampling methods, such as cryobiopsy for peripheral tumor lesions or cytoblock obtained by ultrasound-guided transbronchial needle aspiration (TBNA), enables obtaining adequate small biopsies and cytological samples for molecular testing, which have until recently been considered unsuitable for this type of analysis. During LC patients’ treatment, resistance occurs due to changes in the mutational tumor status or pathohistological tumor type. Therefore, the repeated taking of liquid biopsies for molecular analysis or rebiopsy of tumor tissue for new pathohistological and molecular profiling has recently been mandated. Conclusions: In thoracic oncology, preference should be given to the least invasive diagnostic procedure providing a sample for histology rather than for cytology. However, there is increasing evidence that, when properly processed, cytology samples can be sufficient for both the cancer diagnosis and molecular analyses. A good knowledge of diagnostic procedures is essential for LC diagnosing and treatment in the personalized therapy era.

[1]  Joe Y. Chang,et al.  Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Ioan Șimon,et al.  Cryobiopsy in Lung Cancer Diagnosis—A Literature Review , 2021, Medicina.

[3]  Y. Dundar,et al.  First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. , 2021, The Cochrane database of systematic reviews.

[4]  Hui Li,et al.  Clinical application of ultrasound‐guided mediastinal lymph node biopsy through cervical mediastinoscopy , 2020, Thoracic cancer.

[5]  J. Ahn An update on the role of bronchoscopy in the diagnosis of pulmonary disease , 2020, Yeungnam University journal of medicine.

[6]  Lizheng Shi,et al.  Biopsy frequency and complications among lung cancer patients in the United States , 2020, Lung cancer management.

[7]  G. Sotgiu,et al.  Bronchoscopic sampling techniques in the era of technological bronchoscopy. , 2020, Pulmonology.

[8]  W. Klepetko,et al.  Current therapy of KRAS-mutant lung cancer , 2020, Cancer and Metastasis Reviews.

[9]  S. Nomura,et al.  Feasibility and utility of transbronchial cryobiopsy in precision medicine for lung cancer: Prospective single‐arm study , 2020, Cancer science.

[10]  A. Drilon,et al.  KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. , 2020, Cancer treatment reviews.

[11]  L. Yarmus,et al.  An evaluation of diagnostic yield from Bronchoscopy: the impact of clinical/radiographic factors, procedure type and degree of suspicion for cancer. , 2020, Chest.

[12]  Satomu Morita,et al.  Comparison of the Utilities of Cryobiopsy and Forceps Biopsy for Peripheral Lung Cancer , 2019, AntiCancer Research.

[13]  S. Hahn,et al.  First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. , 2019, Clinical lung cancer.

[14]  Jiayuan Sun,et al.  Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer. , 2019, The Annals of thoracic surgery.

[15]  Hojoong Kim,et al.  Diagnostic Performance of Radial Probe Endobronchial Ultrasound without a Guide-Sheath and the Feasibility of Molecular Analysis , 2019, Tuberculosis and respiratory diseases.

[16]  S. C. Wang,et al.  Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  P. Massion,et al.  Cryobiopsy with endobronchial ultrasonography using a guide sheath for peripheral pulmonary lesions and DNA analysis by next generation sequencing and rapid on-site evaluation. , 2019, Respiratory investigation.

[18]  K. Takayama,et al.  Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions , 2019, Cancers.

[19]  Alexandre M. Furman,et al.  Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One‐Year Results of the Prospective, Multicenter NAVIGATE Study , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Geewon Lee,et al.  Molecular analysis of small tissue samples obtained via transbronchial lung biopsy using radial probe endobronchial ultrasound , 2019, PloS one.

[21]  A. Yılmaz,et al.  Adequacy of EBUS‐TBNA specimen for mutation analysis of lung cancer , 2019, The clinical respiratory journal.

[22]  H. Groen,et al.  First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis , 2019, OncoTargets and therapy.

[23]  J. Luketich,et al.  Making cold malignant pleural effusions hot: driving novel immunotherapies , 2019, Oncoimmunology.

[24]  J. Jett,et al.  Comparison of Programmed Death Ligand‐1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens , 2018, Chest.

[25]  A. Majid,et al.  Adequacy of Samples Obtained by Endobronchial Ultrasound with Transbronchial Needle Aspiration for Molecular Analysis in Patients with Non‐Small Cell Lung Cancer. Systematic Review and Meta‐Analysis , 2018, Annals of the American Thoracic Society.

[26]  Jian Zhang,et al.  The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis , 2018, Cancer medicine.

[27]  P. Swanson,et al.  Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non–Small Cell Lung Carcinomas , 2018, Applied immunohistochemistry & molecular morphology : AIMM.

[28]  C. Dooms,et al.  A Randomized Clinical Trial of Flex 19G Needles versus 22G Needles for Endobronchial Ultrasonography in Suspected Lung Cancer , 2018, Respiration.

[29]  Sharyn I. Katz,et al.  Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  J. Marshall,et al.  Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients , 2018, Cancer medicine.

[31]  B. Sundaram,et al.  Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecula , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Butnor,et al.  Use of an Additional 19-G EBUS-TBNA Needle Increases the Diagnostic Yield of EBUS-TBNA , 2018, Journal of bronchology & interventional pulmonology.

[33]  T. Nagayasu,et al.  Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer , 2017, PloS one.

[34]  M. Salido,et al.  Heterogeneity of Tumor and Immune Cell PD‐L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples , 2017, Clinical lung cancer.

[35]  K. Lu,et al.  Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer , 2017, Chronic diseases and translational medicine.

[36]  M. Burotto,et al.  Molecular Testing of EGFR, EGFR Resistance Mutation, ALK and ROS1 Achieved by EBUS-TBNA in Chile. , 2017, Archivos de bronconeumologia.

[37]  Gonzalo Labarca,et al.  Análisis moleculares de EGFR, mutación de resistencia al EGFR, ALK y ROS1 en muestras obtenidas mediante PATB-USEB en Chile , 2017 .

[38]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[39]  Chunrong Lin,et al.  Central airway tumors: interventional bronchoscopy in diagnosis and management. , 2016, Journal of thoracic disease.

[40]  L. Thiberville,et al.  Molecular analysis of peripheral non‐squamous non‐small cell lung cancer sampled by radial EBUS , 2016, Respirology.

[41]  Y. Hiraishi,et al.  Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer , 2016, Lung.

[42]  M. Wahidi,et al.  Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report. , 2016, Chest.

[43]  C. Tinelli,et al.  Randomized Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration With and Without Rapid On-site Evaluation for Lung Cancer Genotyping. , 2015, Chest.

[44]  H. Asamura,et al.  Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer. , 2015, Clinical lung cancer.

[45]  L. Sequist,et al.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. , 2015, The Lancet. Oncology.

[46]  L. Pantanowitz,et al.  Adequacy of core needle biopsy specimens and fine-needle aspirates for molecular testing of lung adenocarcinomas. , 2015, American journal of clinical pathology.

[47]  A. Jekunen Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments , 2015, Journal of oncology.

[48]  L. Ofiara,et al.  Optimizing Tissue Sampling for the Diagnosis, Subtyping, and Molecular Analysis of Lung Cancer , 2014, Front. Oncol..

[49]  Dan Liu,et al.  Malignant Pleural Effusion Supernatants Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients with Advanced Lung Adenocarcinoma , 2014, PloS one.

[50]  R. Whatley,et al.  Cryobiopsy: Should This Be Used in Place of Endobronchial Forceps Biopsies? , 2013, BioMed research international.

[51]  Jie Yang,et al.  Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. , 2013, Lung cancer.

[52]  Yue Yu,et al.  Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis , 2013, Frontiers of Medicine.

[53]  M. Ladanyi,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[54]  J. Koo,et al.  EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. , 2011, Clinical lung cancer.

[55]  T. Beyer,et al.  Cryobiopsy increases the diagnostic yield of endobronchial biopsy: a multicentre trial , 2011, European Respiratory Journal.

[56]  F. J. F. Herth,et al.  Bronchoscopic techniques in diagnosis and staging of lung cancer , 2011, Breathe.

[57]  Y. Onodera,et al.  Endobronchial ultrasonography with guide-sheath for peripheral pulmonary lesions , 2004, European Respiratory Journal.

[58]  N. Kurimoto,et al.  Analysis of the internal structure of peripheral pulmonary lesions using endobronchial ultrasonography. , 2002, Chest.

[59]  T. Marcy Transthoracic Fine Needle Aspiration (TFNA) , 1999 .

[60]  Hodgkin Lymphoma NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[61]  Atul C Mehta,et al.  Evidence-Based Clinical Practice Guidelines Initial Diagnosis of Lung Cancer : ACCP , 2007 .